Accelerate Your Oncology Drug Development with Complete DMPK Analysis

Discovering safe and effective pharmaceutical agents demands speed and accuracy. At our state-of-the-art facility, we offer in vivo pharmacokinetic (PK) services that allow you to rapidly assess the pharmaceutical and safety properties of your new agents. Experience the power of TD2’s pharmacological and bioanalytical drug metabolism and pharmacokinetics (DMPK) platform, enabling you to confidently select the most robust drug formulations and optimize your drug discovery and preclinical development strategies.

At TD2, we understand that each drug development journey is unique, and we are committed to tailoring our DMPK panel to match your candidate’s specific requirements. Coupled with our state-of-the-art and AAALAC-accredited vivarium, you can trust that every sample analysis and result is conducted with the utmost precision, accuracy, and reproducibility.

DMPK Available Services:

DMPK: Drug metabolism and pharmacokinetics (DMPK) is a core discipline in drug development that considers the biotransformation of a drug compound and other pharmacokinetic properties to assess drug safety.

Method Development and Validation/TransferMethod Development and Validation/Transfer

  • Adherent to FDA guidance for the industry

Analysis of biological samples:Analysis of biological samples:

  • Plasma
  • Serum
  • Tissues including but not limited to:
    • Tumor
    • Brain
    • Heart
    • Kidneys
    • Lungs
    • Muscles

Analysis of investigational compounds for <i>in vivo</i> studiesAnalysis of investigational compounds for in vivo studies:

  • Drug concentration verification
  • Efficacy
  • PK

Protein Binding AnalysisProtein Binding Analysisx

  • Plasma
  • Microsomal
  • Tumor/Tissue


  • Hepatic Fractions (S9/Microsomes)
  • Hepatocyte
  • CYP Phenotyping
  • CYP Inhibition


  • Caco-2

Request more information about our DMPK services

Contact our experts to help advance your drug development with TD2's trusted DMPK services.

Mean drug concentration-time curve

Figure 1: Mean drug concentration-time curve of XX inhibitor in plasma and tumor following PO administration (5mg/kg) in XX-tumor bearing mice (n = X)

Group Lines

Test Article




PK Parameter


1 XX inhibitor 5mg/kg PO Once Rsq-Adj 0.99
Half-Life (hr) 2.16
Tmax (hr) 2
Cmax (ng/mL) 6588.66
AUC0-last (hr*ng/mL) 29175.29
AUC0-inf (hr*ng/mL) 29191.16
AUC %Extrap (%) 0.05
Vz/F Obs (mL/kg) 533.09
CI/F Obs 171.28

Table 1: Plasma PK data analysis of the XX inhibitor following a single oral treatment in female nude mice bearing XX subcutaneous tumors.


Advanced biomarker assays and analytical readouts.

Trust your research with a team of oncology experts that keep the end goal in mind. TD2 helps advance screening studies by offering various specialty assays from tumor immune cell infiltrate profiling to quantitation of the effect of therapy on the microbiome. In addition, access a wide range of standard applications through the cutting-edge MesoScale Discovery platform including:

  • Cytokines and chemokines
  • Cell signaling pathways
  • Angiogenesis and hypoxia markers
  • Growth and vascular factors
  • Metabolic markers
  • Cell based assays
  • Phosphoprotein analyses

Advanced biomarker assays and analytical readouts

Preclinical Models and Services


Models and Services

TD2’s service offering is consistently expanding and currently includes:

In vivo and In vitro Characterization

Therapeutic Evaluation:


Work with a team who believes in your research as much as you do.

Are you ready to start your Flow Cytometry studies? Partner with a collaborative oncology CRO that believes in your treatment as much as you do. Take the first step today and contact our experts.